Sandoz Group Ltd

SDZ

Equity

ISIN CH1243598427 / Valor 124359842

SIX Swiss Exchange (2025-10-21)

CHF 48.74+1.09%

Sandoz Group Ltd
UMushroom community rating:

4.50 8 votes No rating yet

NegativeNeutralPositive

About company

Sandoz Group Ltd is a global pharmaceutical company that offers a wide range of biosimilar and generic medicines, providing over 800 million patient treatments annually. With a portfolio of approximately 1,500 quality products, the company plays a significant role in improving healthcare by generating substantial cost savings in the US and Europe, ultimately resulting in a total social impact estimated at around USD 400 billion per year worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Growth

H1 2025 net sales reached USD 5,232 million, increasing by 4% at constant currencies and 6% on a comparable growth rate basis. This growth was primarily fueled by a 12% rise in biosimilars sales and a 1% increase in generics sales at constant currencies.

Biosimilars Performance

Biosimilars sales surged by 12% at constant currencies and 17% at comparable growth rates, now accounting for 29% of total net sales. The segment achieved a milestone in Q2, contributing 30% of net sales, supported by successful product launches and strategic acquisitions.

Financial Metrics

The company’s core EBITDA grew by 18% to USD 1,046 million, with the core EBITDA margin expanding to 20.0% from 17.5% year-on-year. Core diluted earnings per share also saw a substantial increase of 30%, reaching USD 1.46.

Future Outlook

Sandoz confirmed its full-year 2025 guidance, projecting mid-single-digit net sales growth at constant currencies and a core EBITDA margin of approximately 21%. The company anticipates even stronger second-half performance, particularly in North America, supported by ongoing investments in biosimilars and strategic acquisitions.

Summarized from source with an LLMView Source

Key figures

33.1%1Y

%3Y

%5Y

Performance

30.2%1Y

30.1%3Y

30.1%5Y

Volatility